Exelixis
EXEL
#1694
Rank
NZ$20.67 B
Marketcap
NZ$76.79
Share price
-0.02%
Change (1 day)
25.33%
Change (1 year)
Exelixis, Inc. is an American genomics-based drug discovery company and the producer of Cometriq, a treatment for medullary thyroid cancer.

Revenue for Exelixis (EXEL)

Revenue in 2025 (TTM): NZ$3.94 Billion

According to Exelixis's latest financial reports the company's current revenue (TTM ) is NZ$3.96 Billion. In 2024 the company made a revenue of NZ$3.84 Billion an increase over the revenue in the year 2023 that were of NZ$2.89 Billion. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.

Revenue history for Exelixis from 2000 to 2025

Annual revenue

Year Revenue Change
2025 (TTM) NZ$3.94 B2.68%
2024 NZ$3.84 B32.87%
2023 NZ$2.89 B14.05%
2022 NZ$2.53 B20.78%
2021 NZ$2.10 B53.5%
2020 NZ$1.36 B-4.75%
2019 NZ$1.43 B12.89%
2018 NZ$1.27 B99.79%
2017 NZ$0.63 B130.51%
2016 NZ$0.27 B408.9%
2015 NZ$54.31 M69.46%
2014 NZ$32.04 M-15.96%
2013 NZ$38.13 M-33.89%
2012 NZ$57.68 M-84.46%
2011 NZ$0.37 B54.72%
2010 NZ$0.23 B14.8%
2009 NZ$0.20 B2.88%
2008 NZ$0.20 B37.1%
2007 NZ$0.14 B5.77%
2006 NZ$0.14 B26.02%
2005 NZ$0.11 B50.03%
2004 NZ$74.07 M-6.57%
2003 NZ$79.28 M-6.38%
2002 NZ$84.68 M-14.24%
2001 NZ$98.75 M76.75%
2000 NZ$55.87 M

Revenue for similar companies or competitors

Company Revenue Revenue differencediff. Country
GlaxoSmithKline
GSK
NZ$73.31 B 1,750.91%๐Ÿ‡ฌ๐Ÿ‡ง UK
Sanofi
SNY
NZ$82.26 B 1,976.95%๐Ÿ‡ซ๐Ÿ‡ท France
Merck
MRK
NZ$111.19 B 2,707.21%๐Ÿ‡บ๐Ÿ‡ธ USA
Bristol-Myers Squibb
BMY
NZ$83.14 B 1,999.19%๐Ÿ‡บ๐Ÿ‡ธ USA
Amgen
AMGN
NZ$62.26 B 1,472.01%๐Ÿ‡บ๐Ÿ‡ธ USA
Johnson & Johnson
JNJ
NZ$159.50 B 3,927.11%๐Ÿ‡บ๐Ÿ‡ธ USA
Pfizer
PFE
NZ$108.68 B 2,643.88%๐Ÿ‡บ๐Ÿ‡ธ USA
Curis
CRIS
NZ$20.16 M-99.49%๐Ÿ‡บ๐Ÿ‡ธ USA
AVEO Oncology
AVEO
NZ$0.16 B-95.88%๐Ÿ‡บ๐Ÿ‡ธ USA